ClinicalTrials.gg
RecruitingNCT07556185Updated Nov 17, 2026

MedlyPeds Feasibility Study

An interventional study of MedlyPeds App in Pediatric Heart Failure, Congenital Heart Disease (CHD) and Acquired Heart Disease, sponsored by The Hospital for Sick Children. Recruiting at 1 site in Canada. Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by The Hospital for Sick Children · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
8 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies in Heart Defects, Congenital by The Hospital for Sick Children — 3 open to participants now, 3 under way, none of them phase 3. Heart Defects, Congenital · The Hospital for Sick Children.

Planned enrollment
16th of 22
30 · median 47
Started
2026
with 1 other
No phase
13 of 22
3 open now
Registered
21st of 22
by date

Among the 22 studies in Heart Defects, Congenital by The Hospital for Sick Children, this one is the 16th largest by planned enrollment, is one of 2 that started in 2026, is one of 13 with no phase, and was the 21st registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

3 of the 22 studies in Heart Defects, Congenital by The Hospital for Sick Children are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: 8 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Heart Defects, Congenital by The Hospital for Sick Children, or all of them as a file.
02

Study summary

SickKids and UHN have developed MedlyPeds which is a smart phone application designed to remotely monitor patients with heart disease. This is a feasibility study which will enroll up to 30 patients with different types of heart disease to see which patient types may benefit the most from MedlyPeds if it were to be used for clinical monitoring. The study is gathering feedback about the app from patients, parents and clinicians to confirm how it needs to be modified to better serve the purpose in a future trial.

Read the detailed description

This is a prospective cohort study that will enroll up to 30 patients with various types of heart disease and up to 10 clinicians in the MedlyPeds program and follow the participants for 3 months. Quality of life questionnaires will be completed at baseline and 3 months or end of study. Patient participants will complete a questionnaire about MedlyPeds and their experience using the app at 3 month or end of study. A subset of patient participants and clinicians will be asked to complete an interview at the end of the study.

03

Conditions studied

  • Pediatric Heart Failure
  • Congenital Heart Disease (CHD)
  • Acquired Heart Disease
  • Pulmonary Hypertension
  • Post Cardiac Surgery

Keywords

  • Medly
  • Telemonitoring
04

Who can participate

Ages eligible
8 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Consent provided.
  2. Aged 8-18 years of age.
  3. Ability to comply with using Medly (ex. able to stand on the weight scale, able to answer symptom questions, etc.)
  4. Followed at the Hospital for Sick Children Cardiology Clinic for any of the following reasons:

    1. Heart failure of any etiology
    2. Congenital heart disease
    3. Acquired heart disease (eg. Kawasaki disease, rheumatic heart disease, connective tissue disorders etc)
    4. Pulmonary hypertension
    5. Post-cardiac surgery including heart transplant and ventricular assist devices

Exclusion criteria

Exclusion Criteria:

  1. Unable to read or write in English.
  2. Participating in another clinical trial that may confound the results.* *Participant may be re-screened for eligibility at a later date.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    MedlyPeds

    Device: MedlyPeds App

Interventions

  • DeviceMedlyPeds App

    The mobile phone-based telemonitoring system (MedlyPeds) will enable cardiac patients to monitor their weight, blood pressure, and heart rate, using wireless home medical devices. In addition, they will answer questions about their symptoms and wellness using their mobile phone. The device measurements will be automatically and wirelessly transmitted to the mobile phone and then to a data server. Automated and individualized self-care messages, developed with the assistance of healthcare providers, will subsequently be sent to the patient based on the readings and reported symptoms.

06

What researchers measure

Primary outcomes

  1. Percentage of MedlyPeds App Daily Check-In Completion

    The primary outcome for this study is overall app engagement measured by completion of symptom check-ins and entry of clinical information (i.e physiologic parameters) by the subject into the app. The feasibility and acceptability of MedlyPeds will be assessed from feedback from patients, parents and clinicians through the end of study questionnaire and interviews.

    Time frame: 3 months

  2. Feasibility and acceptability of Medly Peds

    The feasibility and acceptability of MedlyPeds will be assessed from feedback from patients, parents and clinicians through the scoring of usefullness and relevance on the end of study questionnaire.

    Time frame: 3 months

Secondary outcomes

  1. Attrition rate

    Change in participants completing MedlyPeds check-ins at baseline compared to the final check-in at Month 3 timepoint

    Time frame: 3 Months

  2. Medication compliance

    Change in estimated number of missed doses of medication from baseline to final check-in

    Time frame: 3 Months

  3. Global impression of change

    Change in Patients' Global Impression of Change Scale (PGIC) from 1-7. Higher values at post-intervention represent a better outcome.

    Time frame: 3 Months

  4. Quality of life related to heart disease

    Change in Cardiac PedsQL (Pediatric Quality of Life Inventory) Uses a 5-point Likert scale (0=never, 4=almost always) with 27 questions.

    Time frame: 3 Months

  5. Self-management

    Change in Adolescent/Young Adult Self-Management and Independence (AMIS II) Scale

    Time frame: 3 Months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2028, 29 months after the start.

Of 208 non-industry interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 29 months is below that.

Counting every sponsor, half of 226 studies reached it within 34 months; a quarter within 17 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2026
First posted
Apr 29, 2026
StartActual
Jul 28, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: date precision and site details
1 update, last Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Minor edits only
    + 2 other changes: date precision and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07556185
Responsible party
Aamir Jeewa (Cardiologist, The Hospital for Sick Children) — Principal investigator
First posted
Apr 29, 2026
Start date
Jul 28, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

Diana Balmer-Minnes
Contact
diana.balmer-minnes@sickkids.ca
416-813-7654 ext. 228624

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion